Outcome of patients with metastatic breast carcinoma treated at a private medical oncology clinic

Cancer

Volumn 88, Issue 1, 2000, Pages 95-107

  Anderson, William F ^a   Reeves, James E ^b   Elias, Abdalla ^c   Berkel, Hans ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Cancer Care Associates   (United States)

^c Glenwood Regional Medical Center   (United States)

^d LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Endocrine therapy; Generalizability; Metastatic breast carcinoma; Patient selection bias

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MEGESTROL ACETATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; COMMUNITY MEDICINE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PRIVATE PRACTICE; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COHORT STUDIES; FEMALE; HUMANS; LOUISIANA; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0033983962     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000101)88:1<95::AID-CNCR14>3.0.CO;2-P     Document Type: Article

References (74)

1. Chu KC, Tarone RE, Kassler LG, Ries LA, Hankey BF, Miller BA,et al. Recent trends In U. S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 1996;88(21): 1571-9.
2. Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 death among 75,000 women. Lancet 1992;339:1-15,71-85.
3. Bearman SI, Shpall EJ, Jones RB, Cagnoni PJ, Ross M. High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. Semin Oncol 1996;23(Suppl 2):60-7.
4. Clark GM, Sledge GW, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5(1): 55-61.
5. Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advance breast cancer. J Clin Oncol 1995;13(8):2043-9.
6. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997;15(10):3171-7.
7. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in Stage I (T1N0M0) and Stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989;7(9): 1239-51.
8. Seidman AD. Chemotherapy for advanced breast cancer: a current perspective. Semin Oncol 1996;23(Suppl 2):55-9.
9. Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998; 16:1669-76.
10. Schapira DV, Urban N. A minimalist policy for breast cancer surveillance. JAMA 1991;265(3):380-2.
11. Norton L. Metastatic breast cancer length and quality of life. N Engl J Med 1991;325:1370-1.
12. Fisher B, Osborne CK, Margolese R, Bloomer W. Treatment of metastatic breast cancer. In: Holland JF, Frei EI, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer medicine, 3rd ed. Philadelphia: Lea & Febiger, 1993:1719.
13. Muss HB. The role of chemotherapy and adjuvant therapy in the management of breast cancer in older women. Cancer 1994;74(7 Suppl):2165-71.
14. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998;90:1205-11.
15. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for Stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-59.
16. Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14(8):2197-205.
17. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer 1999;85:104-11.
18. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997;24(4)(Suppl 10):S10-3-10.
19. Hudis CA, Norton L. Adjuvant drug therapy for operable breast cancer. Semin Oncol 1996;23(4):475-93.
20. Hudis CA, Norton L. Adjuvant drug treatment for resectable breast cancer. Oncologist 1997;2:351-8.
21. Sledge GW. Should we dream the impossible dream? The meaning of long-term survival in metastatic breast cancer. J Clin Oncol 1996;14(8):2191-3.
22. General Accounting Office. Breast cancer patients' survival. Washington, DC: General Accounting Office of the United States, 1989.
23. Mueller CB. The case against the use of adjuvant chemotherapy in breast cancer. Bull Am Coll Surg 1993;78:25-31.
24. Editorial. Breast cancer: have we lost our way? Lancet 1993; 341:343-4.
25. Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997;15(5):1870-9.
26. Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 1996;14(1):66-9.
27. Canellos GP. Selection bias in trials of transplantation for metastatic breast cancer: have we picked the apple before it was ripe? J Clin Oncol 1997;15(10):3169-70.
28. Garcia-Carbonero R, Hidalgo M, Paz-Ares L, Calzas J, Gomez H, Guerra JA, et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol 1997;15(10):3178-84.
29. Savarese DMF, Hsieh C-C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997;15(8): 2981-95.
30. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337(8):536-42.
31. Byar DP. Why data bases should not replace randomized clinical trials. Biometrics 1980;36:336-42.
32. A'Hern RP, Ebbs SR, Baum MB. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 1988;57(6):615-8.
33. Bloom HJG, Richardson WW, Harries EJ. Natural history of untreated breast cancer (1805-1933). Br Med J 1962;2:213-21.
34. Diehl LF, Perry DJ. A comparison of randomized concurrent control groups with matched historical control groups: are historical controls valid? J Clin Oncol 1986;4(7):1114-20.
35. Debonis D, Terz JJ, Eldar S, Hill LR. Survival of patients with metastatic breast cancer diagnosed between 1955 and 1980. J Surg Oncol 1991;48(3):158-63.
36. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Cancer 1977;39(3):1289-94.
37. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al. Breast AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1997:171-80.
38. StatSoft, Inc. Statistica for Windows, version 5.1. Tulsa, OK: Statsoft, Inc., 1998.
39. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
40. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. J R Stat Soc 1972;135(A):18598.
41. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34(B): 187-220.
42. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. New York: John Wiley & Sons, 1982.
43. Simpson JF, Page DL. Status of breast cancer prognostication based on histopathologic data. Am J Clin Pathol 1994; 102(Suppl 1):S3-8.
44. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14(10):2738-46.
45. Rubens RD, Bajetta E, Bonneterre J, Klijn JG, Lonning PE, Paridaens R. Treatment of relapse of breast cancer after adjuvant systemic therapy-review and guidelines for future research. Eur J Cancer 1994;30A(1):106-11.
46. Bonneterre J, Mercier M. Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. Cancer Treat Rev 1993; 19(Suppl B):21-30.
47. Ahmann FR, Jones SE, Moon TE. The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer. J Surg Oncol 1988;37(2):116-22.
48. Moses LE. The series of consecutive cases as a device for assessing outcomes of interventions. In: Bailar JC, Mosteller F, editors. Medical uses of statistics, 2nd ed. Boston: New England Journal of Medicine Books, 1992:125-40.
49. Mueller CB, Jefferies W. Cancer of the breast: its outcome as measured by the rate of dying and causes of death. Ann Surg 1975;182:334-41.
50. Black WC, Welch HG. Advances in diagnostic imaging and overestimation of disease prevalence and the benefits of therapy. N Engl J Med 1993;328(17):1237-43.
51. Shipp MA. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329(14):987-94.
52. Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998;16: 2401-8.
53. Bailar JC. Diagnostic drift in the reporting of cancer incidence. J Natl Cancer Inst 1998;90(11):863-4.
54. Editorial. Assessing the odds [editorial]. Lancet 1998;350: 1563.
55. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993;85(11):892-7.
56. Phillips K-A, Glendon G, Knight JA. Putting the risk of breast cancer in perspective. N Engl J Med 1999;340(2):141-4.
57. American College of Physicians. Oncology medical knowledge self-assessment program. Philadelphia: American College of Physicians, 1999.
58. Falkson G, Gelman R, Falkson CI, Glick J, Harris J. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J Clin Oncol 1991;9(12):2153-61.
59. Muss HB, Case LD, Richards F II, White DR, Cooper MR, Cruz JM, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association [see comments]. N Engl J Med 1991; 325(19):1342-8.
60. Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, et al. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 1991;9(12):2148-52.
61. Daland EM. Untreated cancer of the breast. Surg Gynecol Obstet 1927;44:264-8.
62. Greenwood M. A report On the natural duration of cancer. Rep Public Health Med Subj HMSO 1926;33:1-26.
63. Nathanson IT, Welch CE. Life expectancy and incidence of malignant disease. I. Carcinoma of the breast. Am J Cancer 1936;28:40-53.
64. Norton L. Kinetic concepts in the treatment of breast cancer. Recent Results Cancer Res 1993;127:1-6.
65. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11(6):1132-43.
66. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC,et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement [see comments]. Lancet 1998;352(9127):515-21.
67. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the "Philadelphia" Intergroup Study (PBT-1). Proc Am Soc Clin Oncol 1999;18:1a.
68. Hudis CA, Munster PN. High-dose therapy for breast cancer. Semin Oncol 1999;26:35-47.
69. Gardner B, Feldman J. Are positive axillary nodes in breast cancer markers for incurable disease? Ann Surg 1993;218(3): 270-8.
70. Fox MS. On the diagnosis and treatment of breast cancer. JAMA 1979;241(5):489-94.
71. Cannistra SA. "Cancer defeated": not if, but when - introducing the Biology of Neoplasia Series. J Clin Oncol 1997; 15(11):3297-8.
72. Smith TJ. Knowing when to bow out gracefully. In: Oncology News International, vol 5. New York: 1996:1,22.
73. Smith TJ, Swisher K. Telling the truth about terminal cancer. JAMA 1998;279(21):1746-8.
74. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339(14):974-84.